Drugs / H56
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02375698 | Nov 2014 → Jun 2016 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03265977 | Jun 2018 → Apr 2021 | tuberculosis | Aeras | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H56 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03265977 ↗ |
| Known as | H56 antigen | “H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).” NCT02375698 ↗ |
| Modality | Protein / enzyme biologic | “H56:IC31 contains a fusion protein” NCT02375698 ↗ |
| Route | Intramuscular | “5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56” NCT03265977 ↗ |